Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$28.85 -2.8%	$30.09	$23.62 ▼ $36.45	$4.90B	0.44	1.73 million shs	1.40 million shs
CLDX Celldex Therapeutics	$22.85 -2.2%	$20.64	$14.40 ▼ $47.00	$1.55B	1.13	959,456 shs	964,101 shs
FOLD Amicus Therapeutics	$5.91 -5.3%	$6.06	$5.51 ▼ $12.65	$1.92B	0.51	3.22 million shs	2.98 million shs
LGND Ligand Pharmaceuticals	$124.30 -2.1%	$110.23	$90.29 ▼ $129.90	$2.45B	0.84	116,426 shs	180,252 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-2.83%	-1.80%	-3.29%	+6.07%	+23.45%
CLDX Celldex Therapeutics	-2.18%	+7.13%	+7.48%	+28.37%	-42.23%
FOLD Amicus Therapeutics	-5.29%	-4.98%	-1.99%	-11.79%	-44.40%
LGND Ligand Pharmaceuticals	-2.06%	+7.97%	+10.49%	+18.81%	+28.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.8362 of 5 stars	4.4	1.0	4.2	4.0	2.5	1.9
CLDX Celldex Therapeutics	2.4737 of 5 stars	4.4	1.0	0.0	3.8	0.0	0.0
FOLD Amicus Therapeutics	4.1007 of 5 stars	3.4	1.0	4.3	3.3	0.0	1.9
LGND Ligand Pharmaceuticals	4.0483 of 5 stars	2.5	1.0	4.4	2.1	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.92	41.83% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	119.30% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	174.49% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	18.40% Upside

Current Analyst Ratings Breakdown

Latest CLDX, ALKS, LGND, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/13/2025	ALKS Alkermes	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/2/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.05	$2.58 per share	11.20	$9.05 per share	3.19
CLDX Celldex Therapeutics	$7.02M	216.07	N/A	N/A	$11.26 per share	2.03
FOLD Amicus Therapeutics	$528.29M	3.44	N/A	N/A	$0.65 per share	9.09
LGND Ligand Pharmaceuticals	$167.13M	14.35	$1.57 per share	78.99	$43.95 per share	2.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	13.80	21.06	1.85	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.74	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	33.50	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest CLDX, ALKS, LGND, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
CLDX Celldex Therapeutics	N/A	21.67	21.67
FOLD Amicus Therapeutics	2.02	3.34	2.47
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
CLDX Celldex Therapeutics	4.40%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

CLDX, ALKS, LGND, and FOLD Headlines

Recent News About These Companies

Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating

July 15 at 2:20 PM | msn.com

CenterBook Partners LP Purchases 44,760 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 15 at 9:44 AM | marketbeat.com

Rice Hall James & Associates LLC Sells 7,704 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 14 at 6:35 AM | marketbeat.com

Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 14 at 3:51 AM | marketbeat.com

Stephens Investment Management Group LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 13 at 6:26 AM | marketbeat.com

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - Nasdaq

July 12, 2025 | nasdaq.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 Shares

July 12, 2025 | insidertrades.com

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)

July 11, 2025 | gurufocus.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

July 11, 2025 | marketbeat.com

Ligand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | Benzinga

July 11, 2025 | benzinga.com

Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI

July 10, 2025 | finanznachrichten.de

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 10, 2025 | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What Happened

July 9, 2025 | marketbeat.com

Brokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $146.14

July 8, 2025 | americanbankingnews.com

Calamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 6, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts

July 5, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 4, 2025 | marketbeat.com

Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July

July 2, 2025 | finanznachrichten.de

Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals

July 2, 2025 | quiverquant.comQ

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

July 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends

CLDX, ALKS, LGND, and FOLD Company Descriptions

Alkermes NASDAQ:ALKS

$28.85 -0.84 (-2.83%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$29.33 +0.48 (+1.66%)

As of 09:01 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Celldex Therapeutics NASDAQ:CLDX

$22.85 -0.51 (-2.18%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$22.94 +0.08 (+0.37%)

As of 08:51 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$5.91 -0.33 (-5.29%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$5.96 +0.05 (+0.85%)

As of 08:56 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$124.30 -2.62 (-2.06%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$129.00 +4.70 (+3.78%)

As of 08:30 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time